Eli Lilly — Oct 30, 2025 release

Based on these changes, EPS guidance has been increased to be in the range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis. The company's updated 2025 financial guidance reflects adjustments shown in the reconciliation table below. 2025 Guidance Earnings per share (reported) $21.80 to $22.50 U.S. tax legislation .39 Amortization of intangible assets .43 Asset impairment, restructuring, and other special charges .39 Net losses on investments in equity securities — Earnings per share (non-GAAP) $23.00 to $23.70 Numbers may not add due to rounding 2 The Company defines performance margin as gross margin less R&D, Marketing, Selling, and Administrative and Asset Impairment, Restructuring and Other Charges divided by Revenue. 8 The following table summarizes the company's updated 2025 financial guidance: Prior Updated (1) (2) (3) Revenue $60.0 to $62.0 billion $63.0 to $63.5 billion Performance Margin (4) (reported) 42.0% to 43.5% 43.5% to 44.5% (non-GAAP) 43.0% to 44.5% 45.0% to 46.0% Other Income/(Expense) (reported) ($750) to ($650) million ($700) to ($600) million Other Income/(Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate (reported) Approx. 19% Unchanged Tax Rate (non-GAAP) Approx. 17% Unchanged Earnings per Share (reported) $20.85 to $22.10 $21.80 to $22.50 Earnings per Share (non-GAAP) $21.75 to $23.00 $23.00 to $23.70 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) Guidance includes ac